Dyadic International Reports Q2 2026 Revenue Decline and Increased Net Loss

Dyadic International, Inc. reported its financial results for the second quarter of 2026, revealing total revenue of $961,138, a slight decrease of 0.6% from $966,630 in the same period of 2025. For the first half of 2026, revenue increased significantly by 52.3% to $2,072,094, compared to $1,360,202 in the prior year. The growth in revenue was primarily driven by a substantial rise in grant revenue, particularly from activities under the Coalition for Epidemic Preparedness Innovations (CEPI) and Gates Foundation grants, which contributed to a $610,965 increase in grant revenue for the six-month period. However, the company also experienced a decrease in research and development revenue due to fewer collaboration activities and the absence of milestone revenue recognized in the previous year.

The company's total costs for the second quarter rose to $984,165, an increase of 60.4% from $613,591 in the prior year, largely due to higher costs associated with grant revenue. For the first half of 2026, total costs surged by 94.9% to $1,776,005, driven by increased expenses related to grant activities. Research and development expenses decreased by 47.2% in the second quarter to $332,621, reflecting a reduction in active internal research initiatives. Conversely, general and administrative expenses rose by 17.6% to $1,689,863 in the second quarter, attributed to higher rebranding and business development costs.

Dyadic's net loss for the second quarter was $2,123,884, compared to a loss of $1,793,774 in the same quarter of 2025, marking an 18.4% increase in losses. For the first half of 2026, the net loss was $4,078,567, a 6.7% increase from $3,821,353 in the prior year. The company cited higher operational costs and a decrease in revenue from research activities as contributing factors to the increased losses.

In terms of strategic developments, Dyadic has made significant progress in its commercialization efforts, including the shipment of six distinct recombinant protein products and the initiation of commercial sales for several products in collaboration with partners. The company has also expanded its pipeline in food and nutrition, with ongoing scale-up activities for recombinant proteins. Additionally, Dyadic has secured funding through various grants, including a $3.1 million grant from the Gates Foundation and a $4.5 million grant from CEPI, which are aimed at advancing its C1 platform for vaccine development.

Looking ahead, Dyadic faces substantial doubt regarding its ability to continue as a going concern, as indicated in its financial statements. The company is actively pursuing additional capital through equity offerings and grant applications to mitigate this risk. Management's plans include executing commercial pilot sales and obtaining licensing revenue, with the expectation of generating recognized sales revenues in the latter half of 2026. However, the success of these initiatives remains uncertain, and the company acknowledges the challenges it faces in achieving its financial and operational goals.